C
16.05
0.24 (1.52%)
| Previous Close | 15.81 |
| Open | 15.77 |
| Volume | 389,599 |
| Avg. Volume (3M) | 602,742 |
| Market Cap | 2,063,532,288 |
| Price / Sales | 236.54 |
| Price / Book | 7.19 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,268.45% |
| Diluted EPS (TTM) | -1.55 |
| Total Debt/Equity (MRQ) | 29.85% |
| Current Ratio (MRQ) | 13.29 |
| Operating Cash Flow (TTM) | -146.31 M |
| Levered Free Cash Flow (TTM) | -91.92 M |
| Return on Assets (TTM) | -24.54% |
| Return on Equity (TTM) | -55.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Bullish | Bullish |
Stockmoo Score
0.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.46% |
| % Held by Institutions | 77.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2024 | 19,963,157 |
| General Atlantic, L.P. | 30 Jun 2024 | 9,681,818 |
| Ecor1 Capital, Llc | 30 Jun 2024 | 5,714,404 |
| First Light Asset Management, Llc | 30 Jun 2024 | 4,780,560 |
| Vida Ventures Advisors, Llc | 30 Sep 2024 | 3,931,818 |
| Tcg Crossover Management, Llc | 30 Jun 2024 | 2,890,816 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (BMO Capital, 118.07%) | Buy |
| Median | 25.00 (55.76%) | |
| Low | 14.00 (Oppenheimer, -12.77%) | Buy |
| Average | 25.17 (56.82%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 14.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 19 Sep 2024 | 33.00 (105.61%) | Buy | 15.85 |
| Morgan Stanley | 19 Sep 2024 | 26.00 (61.99%) | Buy | 15.85 |
| BMO Capital | 16 Sep 2024 | 35.00 (118.07%) | Buy | 16.46 |
| 09 Sep 2024 | 20.00 (24.61%) | Buy | 14.93 | |
| Guggenheim | 11 Sep 2024 | 24.00 (49.53%) | Buy | 13.75 |
| Jefferies | 11 Sep 2024 | 19.00 (18.38%) | Buy | 13.75 |
| Oppenheimer | 14 Aug 2024 | 14.00 (-12.77%) | Buy | 12.60 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |